Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.

[1]  M. Osaki,et al.  Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. , 2005, Anticancer research.

[2]  L. Kiesel,et al.  Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ , 2005, British Journal of Cancer.

[3]  U. Thorgeirsson,et al.  A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells. , 2005, Anticancer research.

[4]  S. Natsugoe,et al.  Impact of Vascular Endothelial Growth Factor-C and -D Expression in Human Pancreatic Cancer , 2004, Clinical Cancer Research.

[5]  P. Carmeliet,et al.  Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. , 2004, Biochemical and biophysical research communications.

[6]  Y. Nagashima,et al.  The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. , 2004, International journal of molecular medicine.

[7]  S. Fox,et al.  Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1α) and the HIF-1α target gene DEC1, but not lymph node metastasis in primary human breast carcinomas , 2004, Journal of Clinical Pathology.

[8]  S. Stacker,et al.  Molecular regulation of the VEGF family – inducers of angiogenesis and lymphangiogenesis , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[9]  S. Stacker,et al.  Lymphangiogenic growth factors as markers of tumor metastasis , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  F. Schmitt,et al.  Angiogenesis: now and then , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[11]  O. Bairey,et al.  All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. , 2004, Leukemia research.

[12]  K. Chayama,et al.  Expression of VEGF‐C and VEGF‐D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma , 2004, Cancer science.

[13]  G. Pillai,et al.  The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study , 2003, Histopathology.

[14]  D. Charnock-Jones,et al.  Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Qifeng Yang,et al.  Clinicopathological Significance of Vascular Endothelial Growth Factor-C in Breast Carcinoma with Long-Term Follow-Up , 2003, Modern Pathology.

[16]  Ichiro Mori,et al.  Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  S. Takeno,et al.  Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma , 2003, Cancer.

[18]  P. Athanassiadou,et al.  Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. , 2002, Human pathology.

[19]  S. Stacker,et al.  The role of tumor lymphangiogenesis in metastatic spread , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  Dihua Yu,et al.  ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma , 2002, Cancer.

[21]  D. Witte,et al.  Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. , 2002, Anticancer research.

[22]  T. Ichikura,et al.  Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF‐C in gastric carcinoma , 2001, Journal of surgical oncology.

[23]  K. Chayama,et al.  Clinicopathological significance of vascular endothelial growth factor (VEGF)‐C in human esophageal squamous cell carcinomas , 2001, International journal of cancer.

[24]  T. Veikkola,et al.  Signalling via vascular endothelial growth factor receptor‐3 is sufficient for lymphangiogenesis in transgenic mice , 2001, The EMBO journal.

[25]  K. Sugimachi,et al.  Clinical significance of vascular endothelial growth factor‐C (VEGF‐C) in breast cancer , 2001, Breast Cancer Research and Treatment.

[26]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[27]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[28]  S. Fox,et al.  The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  P. Athanassiadou,et al.  DNA Topoisomerase II-Alpha Immunoreactivity as a Marker of Tumor Aggressiveness in Invasive Breast Cancer , 2000, Pathobiology.

[30]  R. Moritz,et al.  Biosynthesis of Vascular Endothelial Growth Factor-D Involves Proteolytic Processing Which Generates Non-covalent Homodimers* , 1999, The Journal of Biological Chemistry.

[31]  G. Tsongalis,et al.  Prevalence of the C282Y and H63D polymorphisms in a multi-ethnic control population. , 1999, International journal of molecular medicine.

[32]  V. J. Venema,et al.  VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. , 1999, Biochemical and biophysical research communications.

[33]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Y. Inayama,et al.  Mutations in the p53 gene in pulmonary blastomas. , 1997, Human pathology.

[35]  Yihai Cao,et al.  Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.

[36]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[37]  S. Pinder,et al.  Histological grading of breast carcinomas: a study of interobserver agreement. , 1995, Human pathology.

[38]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Nicholson,et al.  A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. British Quality Control Group. , 1991, European journal of cancer.

[40]  J. Partanen,et al.  Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins , 2004, Nature Immunology.

[41]  D. Ribatti,et al.  A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. , 2003, Haematologica.

[42]  G. Neufeld,et al.  The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. , 2002, Advances in experimental medicine and biology.